Cytiva Fibro PrismA tech used in LifeArc’s COVID-19 research

Fibro PrismA, the first product based on Cytiva’s protein A fiber chromatography technology, was made available commercially earlier this year

LifeArc has used PrismA from Cytiva to accelerate purification timelines on a COVID-19 project from 14 to five days.

The Fibro chromatography technology enables rapid cycling antibody purification. In clinical and commercial manufacturing, the technology will enable efficient single-use operations by using the full unit lifetime in a single batch.

LifeArc, an independent medical research charity in the UK, was one of the first organizations to perform technical evaluations on Fibro PrismA. Research scientists were reportedly able to significantly reduce purification times from an average of 110 minutes to less than 16 minutes. Most recently, LifeArc applied the technology in a COVID-19 project where it was able to reduce timelines from 14 to five days.

Dr Kovilen Sawmynaden, Principal Scientist at LifeArc, said: “The main benefits of Fibro PrismA are speed and efficacy. As an organization that focuses on translation and progressing work from early lab-based findings, Fibro PrismA is helping us to accelerate the research that brings transformative medicines to patients. We have seen an immediate impact on project timelines, including some of our Covid-19 related work.”

Olivier Loeillot, senior vice president, Bioprocess Cytiva, said: “Speed and flexibility are what our customers need to advance the development of novel therapeutics. Fibro PrismA enables ultrafast purification in research and process development allowing researchers to accelerate the drug discovery process.”

The first commercially available solutions: HiTrapTM Fibro PrismA and HiScreenTM Fibro PrismA, are designed for research and process development.

Companies